| IPO Company Profile |
| SEC Filings | Peer IPO Companies |
| UroSurge, Inc. |
| 2660 Crosspark Road, Coralville, IA 52241 * (319) 626-8311 |
| The company designs, develops, manufactures and markets medical devices for the treatment and management of genito-urinary disorders. |
| Manager | Tier | Phone |
| Donaldson, Lufkin & Jenrette Securities Corp. | Lead Manager | (212) 371-0641 |
| CIBC Oppenheimer & Company | Co-manager | (212) 667-7400 |
| NASNTL: | URSG | Manufacturing: | SIC 3845 | |
| Type of Shares: | Common Shares | Filing Date: | 4/9/98 | |
| U.S. Shares Filed: | 0 | Filing Price: | - | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $40,480,000 | |
| Primary Shares: | 0 | Expenses: | - | |
| Secondary Shares: | 0 | Post-IPO Shares: | ||
| Employees: | 34 |
| Issuer's Law Firm: | Wilson, Sonsini, Goodrich & Rosati |
| Bank's Law Firm: | Sullivan & Cromwell |
| Registrar/Transfer Agent: | Norwest Bank of Minnesota |
| Auditor: | McGladrey & Pullen |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 12/31/97 | 12/31/97 | ||||
| Revenue: | $11.71 | Assets: | $5.53 | ||
| Net Income: | -$5.25 | Curr Assets: | $4.49 | ||
| EPS: | -$0.84 | Liabilities: | $1.05 | ||
| Prior EPS: | Curr Liab: | $0.94 | |||
| Cash Flow/Oper: | -$5.67 | Equity: | $4.47 | ||
| Cash Flow/Fin: | $7.35 | Cash: | $3.27 | ||
| Cash Flow/Inv: | -$3.66 | Working Cap: | $3.54 | ||
| Use of Proceeds |
| The proceeds from the proposed offering will be used for increased research and development, including clinical trials, expansion of sales and marketing activities, expansion of manufacturing capabilities and general corporate purposes including working capital. |